ArticleClinical case reports2026
Aggressive Desmoplastic Small Round Cell Tumor in an Adult: A Case Report and Literature Review.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Desmoplastic small round cell tumor (DSRCT) is a rare and highly aggressive sarcoma that predominantly affects adolescents and young adults. It is defined by a characteristic chromosomal translocation, t(11;22) (p13;q12), resulting in the EWS-WT1 fusion gene. Owing to its rarity and aggressive behavior, optimal treatment strategies remain poorly established. We report the case of a 35-year-old male who presented with progressive abdominal pain, bloating, and early satiety. Imaging revealed an intra-abdominal mass, and histopathological evaluation with immunohistochemistry confirmed the diagnosis of DSRCT. Molecular confirmation of the EWS-WT1 fusion was not performed. The patient underwent cytoreductive surgery followed by early postoperative intraperitoneal chemotherapy (EPIC) and intensive systemic chemotherapy. Although initial disease control was achieved, the patient subsequently developed peritoneal recurrence and isolated liver metastasis requiring multiple lines of salvage chemotherapy and liver metastasectomy. Despite aggressive multimodal management, the disease demonstrated progressive chemoresistance. DSRCT is characterized by an aggressive clinical course with a high risk of recurrence and distant metastasis. This case is distinguished by adult age at presentation, the use of EPIC combined with systemic therapy, liver metastasectomy, and a relatively prolonged survival compared with historical series. It highlights the limitations of current treatment strategies and the urgent need for novel systemic and targeted therapies in DSRCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.